Ma. Teresa M.Mercado

2005-09-13 11:30
(6356 d 12:24 ago)

Posting: # 31
Views: 18,024

 Conduct of Study [Bioanalytics]

May I know the conduct of BA/BE in your labs.
Are all subjects done in 1 instrument (HPLC) by 1 researcher or in 3 different HPLCs by 3 diff researchers.
Vienna, Austria,
2005-09-19 18:18
(6350 d 05:36 ago)

@ Ma. Teresa M.Mercado
Posting: # 32
Views: 13,308

 Conduct of Study

Hi Teresa!

Samples from subjects should be analyzed in a cross-over manner, i.e., sample1/period1–sample1/period2, sample2/period1–sample2/period2, etc., thus avoiding sample carry-over – which could be a major issue if analyzing samples at random.

If possible (no time pressure), samples from the entire should be run by the same analyst on one machine.

We once got problems during an inspection (analyses were performed on three identical machines), and the inspectors wanted us to show that the results from the three instruments were ‘interchangeable’, which is clearly nonsense (since a complete set of calibrators and QCs was run in all batches on each instrument), but we had to show it anyhow.

If you have to run the analytical part faster, I would suggest to show ‘no differences between machines’, i.e., run one complete set of calibrators and QCs on each machine and demonstrate statistically no difference (e.g., paired t-test: equality of intercept and slope of regression line, or orthogonal regression [also known as unweighted Deming regression] of responses from both machines for intercept=0 and slope=1).

If you plan to include more than one machine in actual runs, it would be wise to include such a demonstration as a part of your pre-study validation.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
21 visitors (0 registered, 21 guests [including 15 identified bots]).
Forum time: 22:54 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz